Navigation Links
Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase III clinical trial data presented today at the XXI International Society on Thrombosis and Haemostasis (ISTH) Congress demonstrate that once-daily rivaroxaban achieved superior efficacy in the prevention of venous thromboembolism (VTE) in patients undergoing knee replacement surgery in a head-to-head comparison with enoxaparin, the current standard of care. Patients in the RECORD3 (REgulation of Coagulation in major Orthopaedic surgery reducing the Risk of DVT and PE) study who were treated with rivaroxaban demonstrated a 49% relative risk reduction (RRR) (p less than 0.001) in the composite primary endpoint of deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE) and all-cause mortality compared to those treated with enoxaparin. A 62% reduction of risk (p=0.01) for developing major VTE (the composite of proximal DVT, non-fatal PE and VTE-related death) - the secondary endpoint of the trial - was observed in the patients treated with rivaroxaban. Rivaroxaban also demonstrated a similarly low rate of major bleeding compared to enoxaparin (0.6% and 0.5%, respectively).

Rivaroxaban is an investigational, oral, once-daily direct Factor Xa inhibitor. It is an anticoagulant - a drug designed to prevent and treat blood clots - in advanced clinical development for the prevention and treatment of thrombosis in acute and chronic settings, enabling convenient administration in both the hospital and at home.

Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development L.L.C. (J&JPRD), and Bayer HealthCare AG.

Lead RECORD3 investigator, Michael R. Lassen, MD, of Hoersholm Hospital, University of Copenhagen, Denmark, commented: "The RECORD3 results are exciting, as they indicate that rivaroxaban may better meet the needs of many patients undergoing orthopaedic surgery. It's an important step for t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:12/17/2014)... and RALEIGH, N.C. ... Marketing Communications, LLC (CTMC), and Integrated Clinical Trial ... recruitment and retention for clinical trials announce that ... Clinical Trial Marketing Services (i-CTMS). i-CTMS will provide ... services to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... 15, 2014 Registreer nu via  ... und 20. Februar sind alle akkreditierten pharmazeutischen ... ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, der ... die neue profitablen Unternehmensdienstleistungen, die für Apotheken ...
(Date:12/15/2014)... 12, 2014 Research and Markets ( ... "Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Electrocardiogram Devices ... 2016. The North America accounts ... while Europe claims approximately 27% ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... , SAN FRANCISCO, Jan. 11, 2010 Amylin Pharmaceuticals, ... priorities that will position the Company to address the dual ... by the end of the year and place the Company ... 2011. The news was presented by Daniel M. Bradbury, president ...
... , FRANKLIN LAKES, N.J., Jan. 11 ... today that it will conduct a live webcast of its first ... at 10:00 a.m. (ET). BD will issue a press release ... the conference call, along with related slides, will be accessible through ...
Cached Medicine Technology:Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference 2Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference 3BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call 2
(Date:12/21/2014)... (PRWEB) December 21, 2014 Over the ... performance issues in hundreds of emergency departments across the ... Its findings have been translated into an innovative suite ... to correct deficiencies and enhance the patient experience. ... emergency physician staffing and management services for hospitals, announced ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings on ... clots from using testosterone products such as AndroGel and ... the male hormone testosterone may increase the risk of ... the Proceedings of the National Academy of Sciences in ... male rats with naturally occurring colon cancer. Dr. Amos-Landgraf, ...
(Date:12/21/2014)... Concept Plus, LLC. a SDB and 8(a) certified ... today announced it has been recognized by Washington Technology ... the fastest growing government contracting small businesses by calculating their ... is the first year that Concept Plus, LLC., participated in ... 95.92% compound annual growth rate. “For Concept Plus to be ...
(Date:12/20/2014)... a distinguished special dress supplier, has just done something ... cut prices to all its prom dresses already, offering ... Many of the hottest styles are sold here like ... more. , A spokesman for MissyDress says, “The great ... prom dresses or sweetheart chiffon prom dresses, you will ...
(Date:12/20/2014)... Dress company LunaDress has recently announced its ... Christmas Sale, offering big discounts on all of its special ... idea to own a perfect wedding gown. If you have ... then come to LunaDress. Many different wedding dress styles and ... website now and enjoy the current special offer, up to ...
Breaking Medicine News(10 mins):Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2
... combined estrogen/progestin hormone-replacement therapy for three years or ... various forms of lobular breast cancer, according to ... Research Center., Previous research indicated that five or ... to increase overall breast-cancer risk, said Christopher I. ...
... Six Worldwide Cruises Feature Interactive Learning from Medical ... new strategies for,heart-healthy living to understanding how the ... cruises in 2008 can learn,about the latest health ... Cleveland Clinic, one of the nation,s most respected ...
... 14 Caraco Pharmaceutical,Laboratories, Ltd., (Amex: CPD ... Drug,Administration (FDA) has granted final approval for the ... 2.5/250 mg, 2.5/500 mg and 5/500 mg,(Glipizide/Metformin HCl)., ... as an adjunct,to diet and exercise, to improve ...
... ORCHARD PARK, N.Y., Jan. 14 MINRAD,International, Inc. (Amex: ... the appointment of Charles R. Trego, Jr. as the ... 3, 2008.,Mr. Trego is joining MINRAD from Hardinge, Inc., ... Vice President since October 2005.,Before that, he served as ...
... prospective study of pain,in adults with sickle cell disease ... than previous large studies have indicated., Authors of ... patients,to record daily pain and indicate whether they used ... estimates about sickle,cell pain assumed that if patients didn,t ...
... ChemoOrders.com Improves the Way Doctors and Nurses Prescribe Chemotherapy ... ... Georgia Cancer Specialists (GCS) wants,to change the way oncology professionals ... and nurses,administer current chemotherapy protocols in a more accurate and efficient,manner. ...
Cached Medicine News:Health News:Combined HRT increases risk of lobular breast cancer fourfold after just 3 years of use 2Health News:Wellness Experts From Cleveland Clinic Set for 2008 Crystal Voyages 2Health News:Wellness Experts From Cleveland Clinic Set for 2008 Crystal Voyages 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R) 2Health News:MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP 2Health News:MINRAD International, Inc. Announces Appointment of Charles R. Trego, Jr. to CFO & EVP 3Health News:Sickle Cell Disease Pain Can Occur Daily and Is Much More Severe Than Previously Thought 2Health News:Local Oncology Group Leads Online Effort to Revolutionize Cancer Care 2
... to facilitate an arthrodesis, either by an ... cages allowing radicular compression by restoring the ... of the foramina, which in turn enhances ... major lumbar instabilities.,CC cages are made of ...
... The PACHETT 3 uses the exact enhanced ... the DGH pachymeters used exclusively by the ... built into the software. The new backlit ... running average, standard deviation and IOP correction ...
... Already, the most advanced motor driven ... easier and faster to learn and operate. ... maintaining accuracy and precision. Our software makes ... easy transition from manual instruments or other ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
Medicine Products: